Why Single Pharmacogenomic Trials Should be Very Significant?Clive E Bowman*
School of Mathematical Sciences, The University of Reading, United Kingdom
- *Corresponding Author:
- Clive E Bowman
School of Mathematical Sciences
The University of Reading, Whiteknights
Reading, RG6 6AH, United Kingdom
Tel: 44 7810 506362
E-mail: [email protected]
Received date: May 28, 2014; Accepted date: May 29, 2014; Published date: June 06, 2014
Citation: Clive E Bowman (2014) Why Single Pharmacogenomic Trials Should be Very Significant?. J Pharmacogenomics Pharmacoproteomics 5:e138. doi: 10.4172/2153-0645.1000e138
Copyright: © 2014 Bowman CE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recasting traditional frequentist thinking into Bayesian beliefs illustrates that requirements for 'strength of evidence' should drive the sizing of pharmacogenomic trials not hopeful hyperbolae. There is no 'free lunch' in pharmacogenomic investigations.